Title:
TREATMENT AND DIAGNOSIS OF CANCER OR INFECTIOUS DISEASE USING RECOGNITION MECHANISM OF T CELL RECEPTOR
Document Type and Number:
WIPO Patent Application WO/2018/026018
Kind Code:
A1
Abstract:
Provided is a method for treating and diagnosing cancer or an infectious disease using the recognition mechanism of a T cell receptor. An NK cell function enhancer, said NK cell function enhancer comprising as an active ingredient a T cell receptor chimeric protein which is a fused protein consisting of a variable region of a T cell receptor capable of recognizing a cancer-specific antigen or a variable region of a T cell receptor capable of recognizing an antigen specific to a pathogen causative of an infectious disease and the Fc region of immunoglobulin, which binds to an MHC molecule complex of cancer cells to induce down modulation of MHC class 1 molecule complex and thus enables NK cells to recognize the cancer cells and kill the same; and an NK cell function enhancer which imparts to NK cells an ability to recognize cancer cells expressing an MHC class 1 molecule or infected cells infected with a pathogen causative of an infectious disease and thus enables the NK cells to kill the cancer cells or the infected cells by the T cell receptor chimeric protein-dependent cytotoxicity (TDCC) activity.
Inventors:
OGASAWARA KOETSU (JP)
Application Number:
PCT/JP2017/028490
Publication Date:
February 08, 2018
Filing Date:
August 04, 2017
Export Citation:
Assignee:
UNIV TOHOKU (JP)
International Classes:
A61K38/17; A61P31/00; A61P35/00; A61P43/00; C07K19/00; C12P21/00; C12Q1/02
Domestic Patent References:
| WO2015075939A1 | 2015-05-28 |
Foreign References:
| JP2003534821A | 2003-11-25 | |||
| JP2004506021A | 2004-02-26 | |||
| JP2007513326A | 2007-05-24 | |||
| JP2008263950A | 2008-11-06 | |||
| JPH07138297A | 1995-05-30 | |||
| JPH11503014A | 1999-03-23 | |||
| US20210008167A1 | 2021-01-14 | |||
| US20210008167A1 | 2021-01-14 |
Other References:
ZHAO, Q. ET AL.: "Affinity maturation of T- cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential", LEUKEMIA, vol. 29, no. 11, 2015, pages 2238 - 2247, XP002754503, ISSN: 0887-6924, DOI: doi:10.1038/leu.2015.125
MAUREEN M. HUGHES; MARYAM YASSAI; JOHN R. SEDY; TARA D. WEHRLY; CHING‐YU HUANG; OSAMI KANAGAWA; JACK GORSKI; BARRY P. SLECKMAN: "T cell receptor CDR3 loop length repertoire is determined primarily by features of the V(D)J recombination reaction", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 33, no. 6, 9 May 2003 (2003-05-09), Hoboken, USA, pages 1568 - 1575, XP071221575, ISSN: 0014-2980, DOI: 10.1002/eji.200323961
CARD K F,ET AL: "A soluble single-chain T-cell receptor IL-2 fusion protein retains WC-restricted peptide specificity and IL-2 bioactivity", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 53, no. 4, 1 April 2004 (2004-04-01), Berlin/Heidelberg , pages 345 - 357, XP002351550, ISSN: 0340-7004, DOI: 10.1007/s00262-003-0450-3
WEI WANG, AMY K. ERBE, JACQUELYN A. HANK, ZACHARY S. MORRIS AND PAUL M. SONDEL: "NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy", FRONTIERS IN IMMUNOLOGY, vol. 6, 27 July 2015 (2015-07-27), pages 1 - 15, XP055562703, DOI: 10.3389/fimmu.2015.00368
CORKUM CHRISTOPHER P., INGS DANIELLE P., BURGESS CHRISTOPHER, KARWOWSKA SYLWIA, KROLL WERNER, MICHALAK TOMASZ I.: "Immune cell subsets and their gene expression profiles from human PBMC isolated by Vacutainer Cell Preparation Tube (CPT™) and standard density gradient", BMC IMMUNOLOGY, vol. 16, no. 1, 1 December 2015 (2015-12-01), XP093072173, DOI: 10.1186/s12865-015-0113-0
See also references of EP 3494984A4
MAUREEN M. HUGHES; MARYAM YASSAI; JOHN R. SEDY; TARA D. WEHRLY; CHING‐YU HUANG; OSAMI KANAGAWA; JACK GORSKI; BARRY P. SLECKMAN: "T cell receptor CDR3 loop length repertoire is determined primarily by features of the V(D)J recombination reaction", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 33, no. 6, 9 May 2003 (2003-05-09), Hoboken, USA, pages 1568 - 1575, XP071221575, ISSN: 0014-2980, DOI: 10.1002/eji.200323961
CARD K F,ET AL: "A soluble single-chain T-cell receptor IL-2 fusion protein retains WC-restricted peptide specificity and IL-2 bioactivity", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 53, no. 4, 1 April 2004 (2004-04-01), Berlin/Heidelberg , pages 345 - 357, XP002351550, ISSN: 0340-7004, DOI: 10.1007/s00262-003-0450-3
WEI WANG, AMY K. ERBE, JACQUELYN A. HANK, ZACHARY S. MORRIS AND PAUL M. SONDEL: "NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy", FRONTIERS IN IMMUNOLOGY, vol. 6, 27 July 2015 (2015-07-27), pages 1 - 15, XP055562703, DOI: 10.3389/fimmu.2015.00368
CORKUM CHRISTOPHER P., INGS DANIELLE P., BURGESS CHRISTOPHER, KARWOWSKA SYLWIA, KROLL WERNER, MICHALAK TOMASZ I.: "Immune cell subsets and their gene expression profiles from human PBMC isolated by Vacutainer Cell Preparation Tube (CPT™) and standard density gradient", BMC IMMUNOLOGY, vol. 16, no. 1, 1 December 2015 (2015-12-01), XP093072173, DOI: 10.1186/s12865-015-0113-0
See also references of EP 3494984A4
Attorney, Agent or Firm:
HIRAKI & ASSOCIATES (JP)
Download PDF: